Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDN4ZP)

• Drug Name: Lixivaptan Drug Info
• Synonyms: 168079-32-1; VPA-985; WAY-VPA-985; UNII-8F5X4B082E; VPA985; CHEMBL49429; CRTX-080; VPA 985; 8F5X4B082E; N-[3-chloro-4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)phenyl]-5-fluoro-2-methylbenzamide; Lixar; Lixivaptan [USAN:INN]; Lixivaptan (USAN/INN); WAY VPA-985; Lixivaptan (VPA-985); AC1L59LM; WAY-VPA 985; GTPL2238; SCHEMBL1649340; DTXSID00168472; PPHTXRNHTVLQED-UHFFFAOYSA-N; ZINC600399; EX-A1129; BCP09167; BDBM50065115; AKOS022181388; AN-1842; CS-7512; API0009250; NCGC00485402-01; VPA985; BF-Derm1

Indication

Disease Entry	ICD 11	Status	REF
Hyponatraemia	5C72	Phase 3	[1]
Congestive heart failure	BD10	Phase 2	[1]
Skin infection	1F28-1G0Z	Phase 2	[2]

• Cross-matching ID:
  PubChem CID: 172997
  CAS Number: CAS 168079-32-1
  TTD Drug ID: DMDN4ZP

Molecule-Related Drug Atlas

Drug(s) Targeting Histidine decarboxylase (HDC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ALPHA-FMH	DMP9VXQ	Pruritus	EC90	Phase 1	[5]
AMA	DM5JZUB	Discovery agent	N.A.	Investigative	[6]
Brocresine	DM9UF02	Discovery agent	N.A.	Investigative	[7]

Drug(s) Targeting Vasopressin V2 receptor (V2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Desmopressin	DMS3GVE	Diabetic complication	5A2Y	Approved	[8]
Mozavaptan	DMZ905C	Hyponatraemia	5C72	Approved	[9]
Oxytocin	DMDL27I	Autism spectrum disorder	6A02	Approved	[10]
Tolvaptan	DMIWFRL	Autosomal dominant polycystic kidney disease	GB81	Approved	[11]
Conivaptan	DM1V329	Euvolemic hyponatremia	5C72	Approved	[12]
Vasopressin	DMQ2FPC	Diabetes insipidus	5A61.5	Approved	[13]
ATOSIBAN	DMB7WYM	N. A.	N. A.	Phase 4	[14]
Satavaptan	DME5PN3	Acute and chronic heart failure	BD1Z	Phase 3	[15]
SSR149415	DMCMD93	Anxiety disorder	6B00-6B0Z	Phase 2	[16]
ASP-7035	DMTF24A	Nocturia	MF55	Phase 2	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histidine decarboxylase (HDC)	TTV9GOF	DCHS_HUMAN	Inhibitor	[3]
Vasopressin V2 receptor (V2R)	TTK8R02	V2R_HUMAN	Antagonist	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2238).
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020550)
• [3] Clinical pipeline report, company report or official report of Biofrontera (2009).
• [4] Emerging drugs for acute and chronic heart failure: current and future developments. Expert Opin Emerg Drugs. 2007 Mar;12(1):75-95.
• [5] Alpha-Fluoromethylhistidine. Kinetics of uptake and inhibition of histamine synthesis in basophil (2H3) cell cultures. Mol Pharmacol. 1985 Aug;28(2):191-9.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1274).
• [7] Histamine in brain--its role in regulation of seizure susceptibility. Epilepsy Res. 1991 Nov-Dec;10(2-3):111-8.
• [8] Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88.
• [9] Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 368).
• [11] Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J. 2009 May 1;419(3):577-84.
• [12] Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001 Nov 13;104(20):2417-23.
• [13] Vasopressin receptors: structure/function relationships and signal transduction in target cells. J Soc Biol. 2005;199(4):351-9.
• [14] The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4.
• [15] Post-translational import of protein into the endoplasmic reticulum of a trypanosome: an in vitro system for discovery of anti-trypanosomal chemical entities. Biochem J. 2009 Apr 15;419(2):507-17.
• [16] Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22.
• [17] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030285)